27
MAR
2014

Northwest Biotherapeutics to Present at the 4th Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference

Posted By :
Comments : Off
BETHESDA, MD, March 27, 2014 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the 4th Annual “Cancer Immunotherapy: A Long-Awaited Reality” conference being held at the New York Academy of Medicine in New York City on Thursday, March 27 at 2:45 pm ET. During her presentation,...
Read More
12
MAR
2014

NW Bio Refutes False Claims By Adam Feuerstein

Posted By :
Comments : Off
BETHESDA, Md., March 12, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false statements and material distortions made by Adam Feuerstein in an article on Tuesday, March 11. Feuerstein falsely accused NW Bio of manipulating its news by delaying announcement of the Hospital Exemption approval by the Paul Ehrlich...
Read More
10
MAR
2014

NW Bio Announces Two German Approvals: “Hospital Exemption” for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement

Posted By :
Comments : Off
DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator BETHESDA, Md., March 10, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute (“PEI”- the FDA of Germany) of a “Hospital Exemption” early access program under...
Read More
07
MAR
2014

NW Bio Receives Recommendation to Continue with Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Board’s Safety Review

Posted By :
Comments : Off
BETHESDA, Md., March 7, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today, in response to shareholder inquiries, that the Data Safety Monitoring Board (DSMB) has made an unblinded review of the safety data for the Company’s ongoing international Phase III GBM Trial, and has recommended that the trial continue...
Read More
06
FEB
2014

NW Bio to Present at BIO CEO and Investor Conference 2014

Posted By :
Comments : Off
BETHESDA, MD, February 6, 2014 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the BIO CEO and Investor Conference 2014, which is being held in New York on February 10-11, 2014. NW Bio’s presentation will take place on Monday, February 10, at 11:30 a.m. EST in the Basildon Room at...
Read More